HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program:[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.8
  1. Home
  2. /Compound

Benzthiazide

HCID 2343
NotesReactions
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
91-33-8
Standard SMILES
NS(=O)(=O)c1cc2c(cc1Cl)NC(CSCc1ccccc1)=NS2(=O)=O
InChIKey
NDTSRXAMMQDVSW-UHFFFAOYSA-N
Molecular formula
C15H14ClN3O4S3
Average molar mass
431.9 g/mol
Monoisotopic mass
430.9834972

Overview

Benzthiazide is 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema. It has a role as a diuretic and an antihypertensive agent. It is a sulfonamide and a benzothiadiazine.

Names & identifiers

Preferred name
Benzthiazide
IUPAC
3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1λ6,2,4-benzothiadiazine-7-sulfonamide
English name
Benzthiazide
Molecular formula
C15H14ClN3O4S3
Molecular weight
431.94

Names & synonyms

benzthiazide91-33-8BenzothiazideAquatagFovaneExnaDihydrexLemazideUreseFreeurilDiucenEdemex
Show more names
exvap1393P 1393
ExosaltProaquaDiuceneRegulonBenzotiazidaBenzthiazidumFouanePfizer 1393

Database identifiers

CAS
91-33-8
PubChem CID
2343
DTXSID
DTXSID4022658
ChEMBL
CHEMBL1201039
ChEBI
CHEBI:3047
UNII
1TD8J48L61
EC Number
202-061-0

Properties

Computed structural properties

XLogP
1.7
Topological polar surface area
161 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
7
Rotatable bonds
5
Heavy atoms
26
Formal charge
0
Complexity
739

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 3 items

log Kow = 1.31 at pH 6.5

1.7

1.73

OdorCHARACTERISTIC
Taste · 2 items

BITTER TASTE

CHARACTERISTIC

Color/Form · 2 items

Crystals from acetone.

FINE, WHITE, CRYSTALLINE POWDER

Solubility · 3 items

PRACTICALLY INSOL IN WATER, SOL IN ALKALINE SOLN

FREELY SOL IN DIMETHYLFORMAMIDE; SLIGHTLY SOL IN ACETONE; PRACTICALLY INSOL IN ETHER & CHLOROFORM

1.29e-02 g/L

Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Thiazide Diuretics

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

DecompositionWhen heated to decomposition it emits very toxic fumes of sulfoxides, nitroxides, and /hydrogen chloride/.

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]

P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 91 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

FDA Requirements · 1 item

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesSkin Sens. 1 (100%)

Safety & protection

Disposal Methods · 1 item

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxicology

Interactions · 5 items

MANY DIABETIC PATIENTS REGULATED BY CHLORPROPAMIDE OR OTHER SULFONYLUREAS EXHIBIT IMPAIRED DIABETIC CONTROL WHEN ANY THIAZIDE DIURETIC IS ADDED TO DRUG REGIMEN. /THIAZIDE DIURETICS/

Chemistry & industry

Pharmacology

Protein Binding30%
Pharmacodynamics · 1 item

Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na<sup>+</sup>/Cl<sup>-</sup> reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of Action · 6 items

As a diuretic, benzthiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like benzthiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of benzthiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

...BENZOTHIADIIDIDES HAVE DIRECT EFFECT ON RENAL TUBULAR TRANSPORT OF SODIUM & CHLORIDE...INDEPENDENT OF ANY EFFECT ON CARBONIC ANHYDRASE. /THIAZIDE DIURETICS/

...BENEFICIAL EFFECTS /OF THIAZIDES/ APPEAR TO RESULT FROM ALTERED SODIUM BALANCE. ...INITIATION OF TREATMENT...CARDIAC OUTPUT IS DECR & BLOOD VOL... DIMINISHED. ...CHRONIC THERAPY CARDIAC OUTPUT RETURNS TO NORMAL, PERIPHERAL VASCULAR RESISTANCE FALLS &...SMALL REDN IN EXTRACELLULAR WATER & PLASMA VOL. /THIAZIDE DIURETICS/

/DOMINANT ACTION OF THIAZIDES IS TO INCR/ RENAL EXCRETION OF SODIUM & CHLORIDE & ACCOMPANYING VOL OF WATER. ...VIRTUALLY INDEPENDENT OF ACID-BASE BALANCE. ... EVOKE SIGNIFICANT AUGMENTATION OF POTASSIUM EXCRETION. THEY VARY WIDELY IN THEIR POTENCY AS INHIBITORS OF CARBONIC ANHYDRASE. /THIAZIDE DIURETICS/

Related reactions

0 records
New reaction record

No reaction records under the current filter.

Compound notes

Loading…

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Melting Point · 4 items

210-211

231 to 232 °C

Melting point also reported as 238 to 239 °C.

231.5 °C

Physical DescriptionSolid
Stability/Shelf LifeSTABLE IN BOTH LIGHT & AIR
Dissociation Constants6

Physicochemical properties

Melting point
231 · 231-232° (U.S. patent); mp 238-239° (P'an)
Boiling point
680.6 · 680.6±65.0 °C(Predicted)
Density
1.4176 · 1.4176 (rough estimate)
refractive index
1.61 · 1.6100 (estimate)
storage temp.
Refrigerator
solubility
DMSO (Slightly), Methanol (Slightly)
form
Solid
pka
9.57 · 9.57±0.20(Predicted)
color
White to Off-White
Water Solubility
2.8 mg/L · 2.8mg/L(room temperature)
InChI
1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)
InChIKey
NDTSRXAMMQDVSW-UHFFFAOYSA-N
SMILES
NS(=O)(=O)c1cc2c(NC(CSCc3ccccc3)=NS2(=O)=O)cc1Cl
FDA UNII
1 TD8J48L61 · 1TD8J48L61
EPA Substance Registry System
2 H-1,2,4-Benzothiadiazine-7-sulfonamide, · 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide (91-33-8)
UNSPSC Code
12352100 · 12352100
NACRES
22 · NA.22
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
317 · H317-H334
Precautionary statements
261 · P261-P280-P342+P311
Hazard Codes
Xn
Risk Statements
42 · 42/43
Safety Statements
26 · 26-36
WGK Germany
2 · 2
RTECS
8400000 · DK8400000
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
1 Skin · Resp. Sens. 1Skin Sens. 1
Hazardous Substances Data
91 · 91-33-8(Hazardous Substances Data)
Toxicity
50 in · LD50 in mice, rats (mg/kg): >5000, >10000 orally; 410, 422 i.v. (P'an)

CONCURRENT ADMIN OF THIAZIDE DIURETICS & MONOAMINE OXIDASE INHIBITORS MAY INCR HYPOTENSION. /THIAZIDE DIURETICS/

...HYPOKALEMIA MAY INTENSIFY ACTION OF NEUROMUSCULAR BLOCKING AGENTS. ... POTASSIUM-DEPLETING DIURETICS ARE KNOWN TO CAUSE HYPOKALEMIA & MAY ENHANCE THIS EFFECT. /DIURETICS/

...CARDIAC GLYCOSIDE & DIURETIC; DIURETIC-INDUCED HYPOKALEMIA POTENTIATES CARDIOTOXICITY OF GLYCOSIDE. /DIURETICS/

For more Interactions (Complete) data for BENZTHIAZIDE (21 total), please visit the HSDB record page.

Health Effects · 1 item

Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion.

Exposure RoutesAbsorbed in the digestive tract.
Toxicity Summary · 1 item

As a diuretic, benzthiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like benzthiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of benzthiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

Signs and SymptomsSymptoms of overdose include nausea, vomiting, fatigue, urinary problems and drowsiness.
Human Toxicity Excerpts · 3 items

ASYMPTOMATIC HYPERURICEMIA OCCURS FREQUENTLY DURING PROLONGED TREATMENT. ACUTE ATTACK OF GOUT MAY BE PPT IN PATIENTS WITH HISTORY OF GOUT OR IN THOSE WITH RENAL FAILURE, BUT IS OBSERVED ONLY RARELY IN PATIENTS WITHOUT THESE DISABILITIES.

ADVERSE EFFECTS...HYPERSENSITIVITY (...RASH, URTICARIA...FEVER, RESPIRATORY DISTRESS, ANAPHYLACTIC REACTIONS)...GLYCOSURIA...MUSCLE SPASM, WEAKNESS, RESTLESSNESS, BLURRED VISION, & HEMATURIA... /THIAZIDE DIURETICS/

May suppress lactation, but compatible /SRP: with breast feeding/. /Thiazide diuretics, from table/

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Antidote and Emergency TreatmentThiazide diuretic overdose should be treated by immediate evacuation of the stomach followed by supportive symptomatic treatment and monitoring of serum electrolyte concentrations and renal function. /Thiazide diuretic/
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Non-Human Toxicity Values · 5 items

LD50 MOUSE ORAL GREATER THAN 5000 MG/KG

LD50 RAT ORAL GREATER THAN 10000 MG/KG

LD50 DOG ORAL GREATER THAN 5000 MG/KG

RABBIT INTRAVENOUS 410 MG/KG

For more Non-Human Toxicity Values (Complete) data for BENZTHIAZIDE (6 total), please visit the HSDB record page.

Regulatory information

FDA Requirements · 1 item

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Safety data

wgk
2
rtecs
DK8400000
Toxicity
LD50 in mice, rats (mg/kg): >5000, >10000 orally; 410, 422 i.v. (P'an)
risk_code
42/43
Signal word
Danger
Symbol(GHS)
GHS08
hazard_code
Xn
safety_code
26-36
Storage Class
11 - Combustible Solids
Hazard statements
H317-H334
Hazard Classifications
Resp. Sens. 1Skin Sens. 1
Precautionary statements
P261-P280-P342+P311
Hazardous Substances Data
91-33-8(Hazardous Substances Data)

UNILATERAL RENAL INTRA-ARTERIAL INJECTION OF THIAZIDES PRODUCES A UNILATERAL DIURETIC RESPONSE, INDICATING A DIRECT RENAL ACTION. ...THIAZIDES...ACTIVELY SECRETED IN PROXIMAL TUBULE. ... DEPENDING ON THIAZIDE, ITS DOSAGE & SOLUTES MEASURED, ITS ACTION ON ELECTROLYTE TRANSPORT MAY OR MAY NOT BE BLOCKED. /THIAZIDE DIURETICS/

For more Mechanism of Action (Complete) data for BENZTHIAZIDE (11 total), please visit the HSDB record page.

Absorption, Distribution and Excretion · 6 items

Absorbed in the digestive tract.

DIURESIS OCCURS WITHIN 2 HR & LASTS 12-18 HR.

THIAZIDES ARE ABSORBED FROM GI TRACT & OWE THEIR USEFULNESS LARGELY TO THEIR EFFECTIVENESS BY ORAL ROUTE. ABSORPTION IS RELATIVELY RAPID. MOST AGENTS SHOW DEMONSTRABLE DIURETIC EFFECT WITHIN HR AFTER ORAL ADMIN. /THIAZIDE DIURETICS/

IN GENERAL, THIAZIDES WITH RELATIVELY LONG DURATIONS OF ACTION SHOW PROPORTIONATELY HIGH DEGREE OF BINDING TO PLASMA PROTEINS & ARE REABSORBED BY RENAL TUBULES. ... DRUG PASSES READILY THROUGH PLACENTAL BARRIER TO FETUS. ALL THIAZIDES PROBABLY UNDERGO ACTIVE SECRETION IN PROXIMAL TUBULE. /THIAZIDE DIURETICS/

DISTRIBUTED IN EXTRACELLULAR SPACE & /CROSSES/ PLACENTA /& APPEARS IN CORD BLOOD/. ONSET OF DIURETIC ACTION...2 HR...PEAK EFFECT...3 TO 6 HR...APPROX DURATION OF /ACTION OF SINGLE DOSE 12-18 HR/. EXCRETED BY GLOMERULAR FILTRATION & ACTIVE SECRETION IN PROXIMAL TUBULE /HUMAN, ORAL/.

ONSET OF HYPOTENSIVE ACTION...3 TO 4 DAYS, &...ACTION DISSIPATES...1ST WK AFTER DISCONTINUING CHRONIC THERAPY. /APPEARS/ IN MILK OF NURSING MOTHERS /HUMAN, ORAL/.

Cellular LocationsCytoplasm

Uses & manufacturing

Uses · 3 items

THERAP CAT: Diuretic, antihypertensive.

MEDICATION

For the treatment of high blood pressure and management of edema.

Methods of Manufacturing · 2 items

4-AMINO-6-CHLORO-M-BENZENEDISULFONAMIDE IS REACTED WITH CHLOROACETIC ANHYDRIDE TO GIVE 2,3'-DICHLORO-4',6'-DISULFAMOYLACETANILIDE WHICH IS THEN CAUSED TO CONDENSE & CYCLIZE BY TREATMENT WITH BENZYL MERCAPTAN IN PRESENCE OF SODIUM HYDROXIDE. US PATENT 3,111,517.

Prepn: J.M. McManus et al., 136th Am Chem Soc Meet (Atlantic City, Sept 1959) Abstr of Papers, pp 13-O; W.M. McLamore, G.D. Laubach, Ger pat 1,137,740; eidem, U.S. pat 3,440,244 (1962, 1960 both to Pfizer).

Formulations/PreparationsDOSAGE FORMS- TABLETS NF: 50 MG.

Applications

UsesBenzthiazide is a diuretic, antihypertensive agent.

Upstream & downstream products

Upstream raw materials

ChloroacetaldehydeBenzyl mercaptan

Suppliers45 total

北京华美互利生物化工010-56205725 · [email protected]
Career Henan Chemica Co+86-0371-86658258 +86-13203830695 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
上海麦克林生化科技股份有限公司021-50706066 15221275939 · [email protected]
江苏艾康生物医药研发有限公司025-58851090 19370895928 · [email protected]
Aladdin Scientific[email protected]
安耐吉化学&3A(安徽泽升科技股份有限公司)400-0056266 · [email protected]
上海柯维化学技术有限公司021-64609169 18901607656 · [email protected]
銳迪國際科技有限公司18024082417 · [email protected]
湖北扬信医药科技有限公司0714-3999001 19171453112 · [email protected]
天津希恩思生化科技有限公司400 638 7771 · [email protected]
武汉鹏胤药业有限公司13163333255 · [email protected]
天津普西唐生物医药科技有限公司010-60605840 · [email protected]
陕西缔都医药化工有限公司+86-29-87569262 +86-15003564040 · [email protected]
Chongqing jooe co., ltd+86-15223382610 · [email protected]
凯试(上海)科技有限公司021-50135380 · [email protected]
Sigma-Aldrich西格玛奥德里奇(上海)贸易有限公司021-61415566 800-8193336 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
艾吉析科技(上海)有限公司17717235263 17717235263 · [email protected]
sgtlifesciences pvt ltd+91-8790379245 · [email protected]
上海阿拉丁生化科技股份有限公司6206333 13167063860 · [email protected]
风咏生物(AbMole)021-10000000 13000000000 · [email protected]
上海珞珐生化科技有限公司021-51111890 15317326293 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
上海陶术生物科技股份有限公司13564774135 · [email protected]
成都标样生物科技有限公司028-81700200 13308200041 · [email protected]
上海颖心实验室设备有限公司021-021-59178156 15300768757 · [email protected]
湖北扬信医药科技有限公司15374522761 · [email protected]
陕西缔都医药化工有限公司029-81154043 17391733319 · [email protected]
天津希恩思生化科技有限公司400-6387771-6039 18920764717 · [email protected]
上海瀚香生物科技有限公司17754423994 · [email protected]
深圳聚合生化科技有限公司+86-400-002-6226 13028896684 · [email protected]
TargetMol中国(陶术生物)4008200310 15002144251 · [email protected]
上海迈瑞尔生化科技有限公司18621169109 · [email protected]
上海陌孚医药科技有限公司4000862158 18117107507 · [email protected]
ChemeGen 中国18818260767 · [email protected]
北京百灵威科技有限公司18210857532 18210857532 · [email protected]
DAYANG CHEM (HANGZHOU) CO.,LTD+86-88938639 +86-17705817739 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354 · [email protected]
南京世洲生物科技有限公司025-85560043 15850508050 · [email protected]
上海甄准生物科技有限公司18019219489 18901678489 · [email protected]
上海阿摩尔生物科技有限公司13370042665 18916960931 · [email protected]
上海鼓臣生物技术有限公司021-34675735 19147740836 · [email protected]
上海弘渠生物医药科技有限公司88888888888 · [email protected]
湖北清北云研医药科技有限责任公司18162595016; 18162595016 · [email protected]
Additional notes · 1 item

DefinitionChEBI: 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.